X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

LABP

Closed

Landos Biopharma Inc

22.91
-0.02 (-0.09%)
Last Update: 23 May 2024 23:37:00
Yesterday: 22.93
Day's Range: 0. - 0.
Send
When Written:
 
0.2893
Landos Biopharma Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, USA. The company is focused on the development of novel, oral therapeutics for autoimmune diseases. Landos Biopharma's lead product candidate, BT-11, is a first-in-class, oral, gut-restricted therapeutic that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway. The company is also developing other product candidates, including BT-09 for inflammatory bowel disease and BT-15 for rheumatoid arthritis. Landos Biopharma was founded in 2017 and is led by a team of experienced biopharmaceutical executives. The company has raised over $100 million in funding to date from investors including RTW Investments, Perceptive Advisors, and Osage University Partners.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X